The NCI Melanoma and Skin Cancer Steering Committee (MSCSC) was established in 2025. At bi-monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase 2 and phase 3 treatment trials in melanoma and skin cancer. View the MSCSC member roster. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Contact
For more information, contact NCI CCCT Program Director, Elena Schwartz, Ph.D., M.S., at elena.schwartz@nih.gov.